{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","upperLimit":"74","value":"61"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was measured from initial treatment to disease progression or death from any cause, whichever came first. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.\n\nrituximab: Given IV fludarabine phosphate: Given IV melphalan: Given IV sirolimus: Given PO tacrolimus: Given PO or IV allogeneic hematopoietic stem cell transplantation: Undergo APBSCT indium In 111 ibritumomab tiuxetan: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV","id":"OG000","title":"0.4 mCi 90Y-Ibritumomab Tiuxetan"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From the initial treatment to the last disease assessment, up to two years","title":"Progression-free Survival at Two Years","type":"SECONDARY","unitOfMeasure":"percentage of survival probability"}